Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884821 | 0.90 | ACHE (0.42) | NAAAALDH1A1EPHX2SMN1; SMN2ACHE | |
| SCHEMBL2948051 | 0.86 | NAAA (0.43) | NAAAEPHX2ACHE | |
| SCHEMBL2947853 | 0.84 | CA12 (0.34) | NAAAALDH1A1EPHX2 | |
| SCHEMBL1885832 | 0.80 | ADRB2 (0.37) | NAAAALDH1A1SMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL1884824 | 0.80 | NAAA (0.35) | NAAAEPHX2SMN1; SMN2 | |
| SCHEMBL1881697 | 0.80 | ALDH1A1 (0.35) | ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL1891743 | 0.79 | MMP2 (0.36) | NAAAALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL18816752 | 0.78 | ALDH1A1 (0.38) | NAAAALDH1A1SMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL1886217 | 0.77 | ADRB2 (0.36) | ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL2954648 | 0.77 | ACHE (0.49) | NAAAEPHX2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | NAAA 11/4885ALDH1A1 2138/4885EPHX2 747/4885 |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | NAAA 11/4885ALDH1A1 2138/4885EPHX2 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.